主催: 日本毒性学会
Aloe has been used for versatile herbal medications and nutraceuticals throughout the history. However, little is known about the toxicology of aloe and it is of importance to determine a daily intake level to ensure its safety. To examine recommended dietary allowances (RDA) of baby aloe powder (BAP), Sprague-Dawley (SD) rats were orally treated with for 4-weeks at four different concentrations (0, 0.125, 0.5, 2 g/kg body weight (bw)). In this study, neither significant nor dose-dependent effects of BAP were observed in biochemical/hematological analysis, urinalysis, clinical signs, body weight, and food and water consumption. Some biomarkers did change compared with those of control but all of them were in their reference ranges. Based on the results we obtained, the no-observed-adverse-effect level (NOAEL) of the BAP was estimated to be 2 g/kg bw in male SD rats and 2 g/kg bw in female SD rats. Therefore, RDA or ADImax was ≥6.67 mg/kg bw/d [(2000 mg/kg bw/d) ÷ (100 for safety factor) × (3 for modifying factor)], or ≥400 mg for a 60-kg adult. Collectively, these data suggest that the baby aloe powder (BAP) used for this study did not cause any noticeable subacute toxic effects and could be used for nutraceuticals and other applications at concentration ≥400 mg for a 60-kg adult.
Key words: Baby aloe powder (BAP), recommended dietary allowances (RDA), safety, no-observed-effect level (NOAEL).
